PrEParing for long-acting injectable PrEP in the South: perspectives from healthcare providers in Georgia

TitlePrEParing for long-acting injectable PrEP in the South: perspectives from healthcare providers in Georgia
Publication TypePublication
Year of Publication2021
AuthorsHall CDXavier, Smith JC, Driggers RA, Stoller B, Khan Z, Li J, Ignatius EH, Siegler AJ
JournalAIDS Care
Volume33
Issue6
Pagination706-711
Date Published2021 06
ISSN1360-0451
KeywordsAnti-HIV Agents, Georgia, Health Personnel, HIV Infections, Humans, Pre-Exposure Prophylaxis
Abstract

<p>New modalities of Pre-exposure Prophylaxis (PrEP) such as long-acting injectable PrEP (LAI-PrEP) promise increased prevention of HIV transmission; however, similar biomedical interventions have not been met with universal adoption by healthcare providers or populations most affected by HIV. This qualitative study explores healthcare provider considerations for the rollout of LAI-PrEP. Eleven key-informant in-depth interviews were conducted with clinicians who prescribe daily oral PrEP. Participants reviewed a currently proposed LAI regimen and were asked to reflect on its implications for their clinical practice. Interviews were transcribed verbatim and thematically coded, with results organized using the Consolidated Framework for Implementation Research (CFIR). All participants expressed interest in prescribing LAI-PrEP and anticipated that at least some patients would be interested. Participants identified characteristics of the intervention, inner intervention setting, and outer intervention setting that will be influential in bringing LAI-PrEP to scale. Clinicians in the South have unique insights into the challenges of and opportunities for successful rollout of future PrEP regimens. Bringing these insights into a CFIR framework highlights the nuances surrounding LAI-PrEP, including structural concerns such as cost barriers and access to in-person healthcare services. It is critical to address these challenges to ensure successful implementation of new PrEP formulations.</p>

DOI10.1080/09540121.2020.1810616
Alternate JournalAIDS Care
PubMed ID32838546
PubMed Central IDPMC8152107
Grant ListP30 AI060354 / AI / NIAID NIH HHS / United States
R01 MH114692 / MH / NIMH NIH HHS / United States
T32 GM066691 / GM / NIGMS NIH HHS / United States
U19 HD089881 / HD / NICHD NIH HHS / United States